| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Oric Pharmaceuticals, Inc.$10.85
-0.02 (-0.18%)
C 40Pipeline Score Overvalued Pharma · Clinical
Market Cap
861.27 M
EPS
-1.43
P/E Ratio
-
Value Trade
17.36 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
31.44 M
Operating CF
-32.44 M
Total Assets
436.76 M
Total Liabilities
21.20 M
Equity
415.56 M
D/E Ratio
12,345
-2.46 %
Week
-22.32 %
1 Month
-25.51 %
3 Month
-28.09 %
6 Month
-66.72 %
5 Year
-68 %
All Time
Cash Data
Cash Position
281.93 M
Monthly Burn
10.81 M
Runway
24.1 mo
Burn Trend
SEC Filing
May 4, 2026
Overview
Volume
1.07 M
52 Week Range
5.51 - 14.93
% held by Insiders
39.53 %
% held by Institutions
77.3 %
Enterprise Value
582.63 M
Total Shares
97.32 M
Short %
33.64 %
Float Shares
58.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oric Pharmaceuticals, Inc.
401Total events
10Upcoming
71Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 10
2028
T2Timing Guidance
Anticipated primary endpoint readout for rinzimetostat Phase 3 study expected before cash runway ends in 2H 2028
2028
T1Topline Readout
Anticipated primary endpoint readout from first Phase 3 trial for ORIC-114 (enozertinib)
2026-H1
T2Trial Initiation
Initiate Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC
2026-H2
T2Timing Guidance
1L EGFR exon 20 insertion monotherapy data and combination data with SC amivantamab
Event history 391
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 3, 2026
Jun 2026
◆Topline ReadoutORIC-114Clinical Data
Data readout for 1L EGFR exon 20 combination and 1L EGFR atypical cohorts
NSCLC (1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical)source ↗
May 4, 2026
▲Enrollment CompleteORIC-114Trial
Completed enrollment in Phase 1b trial of enozertinib as single-agent in first-line patients
advanced NSCLC with EGFR exon 20 insertion mutationssource ↗
Apr 22, 2026
◆Poster PresentationORIC-944Presentation
Poster presentation at AACR 2026: Rinzimetostat efficacy in PRC2 methyltransferase-resistant settings
prostate cancersource ↗
Apr 17, 2026
◆Poster PresentationORIC-944Presentation
Poster presentation at AACR 2026: Rinzimetostat blockade of PRC2 activity improves response of androgen receptor pathway inhibition across prostate cancer models
prostate cancersource ↗
Q2 2026
◆Topline ReadoutORIC-114Clinical Data
Next data update for 1L patients expected mid-2026
NSCLC with EGFR exon 20 mutationssource ↗
Q2 2026
◆Timing GuidanceORIC-114Presentation
Next update expected in mid-2026 for 1L NSCLC patients with EGFR exon 20 and PACC mutations
NSCLC with EGFR exon 20 and EGFR PACC mutationssource ↗
Q2 2026
◆Topline ReadoutORIC-114Clinical Data
Initial data from Phase 1b combination trial of ORIC-114 with SC amivantamab
advanced NSCLC with EGFR exon 20 insertion mutationssource ↗
Mar 31, 2026
▼Program DiscontinuationORIC-944Corporate
Rinzimetostat (ORIC-944) program update: similar effectiveness as competing drug, falling short of expectations
prostate cancersource ↗
Mar 31, 2026
◆Oral PresentationORIC-944Presentation
Combination dose optimization data from Phase 1b trial of rinzimetostat in mCRPC
metastatic castration resistant prostate cancer (mCRPC)source ↗
Drug Pipeline Intelligence
C40
Pipeline Score $204M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 57%
Micro Cap (rank 393 of 911)
Percentile RankOric Pharmaceuticals, Inc. carries a moderate pipeline score (40/100), with $509M risk-adjusted pipeline value, led by ORIC-944 in Metastatic Prostate Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORIC-944 Small molecule | Metastatic Prostate Cancer | Phase 1 | NCT05413421 | 5% | $177M | RECRUITING | 250 | STALLED | D (37) | Apr 1, 2028 | MODERATE_RISK | MEDIUM Jul 9, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rinzimetostat | post-abiraterone mCRPC | Phase 3 | 2026-05-04 | r PFS rates: 93%, 84%, and 84% at 3, 4, and 5 months, respectively; TRAEs: The vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity; Grade 3 TRAE: A single Grade 3 TRAE was observed, and no Grade 4 or 5 AEs were attributed to rinzimetostat or darolutamide. Read More | ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in Read More | |
rinzimetostat | post-abiraterone mCRPC | Phase 3 | 2026-05-04 | r PFS rates: 93%, 84%, and 84% at 3, 4, and 5 months, respectively; TRAEs: The vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity; Grade 3 TRAE: A single Grade 3 TRAE was observed, and no Grade 4 or 5 AEs were attributed to rinzimetostat or darolutamide. Read More | ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in Read More | |
rinzimetostat | post-abiraterone mCRPC | Phase 3 | 2026-05-04 | r PFS rates: 93%, 84%, and 84% at 3, 4, and 5 months, respectively; TRAEs: The vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity; Grade 3 TRAE: A single Grade 3 TRAE was observed, and no Grade 4 or 5 AEs were attributed to rinzimetostat or darolutamide. Read More | ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ORIC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ORIC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ORIC▼ -6.5%on this news
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, Inc. announced the grant of stock options and restricted stock units to two new employees as part of an inducement effort under Nasdaq Listing Rule 5635(c)(4). The grants, totaling 34,800 non-qualified stock options and 5,900 restricted stock units, come as part of the company's 2022 Inducement Equity Incentive Plan. The vesting schedule for these grants is designed to encourage employee retention, with specific conditions outlined for the options and units. These measures reflect ORIC's strategy to strengthen its workforce as it continues to focus on oncology treatments.
Read more →ORICORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals announced its participation in two upcoming investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Management will engage in fireside chats and hold one-on-one meetings with potential investors. Webcasts of these discussions will be accessible on the company's website for a limited time after the events.
Read more →ORICORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
ORIC Pharmaceuticals announced the grant of 216,000 stock options and 35,000 restricted stock units to four new non-executive employees as part of its 2022 Inducement Equity Incentive Plan. These grants are intended to incentivize retention and were approved by the Compensation Committee in compliance with Nasdaq regulations. The stock options will vest over time, contingent on continued employment.
Read more →ORICORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in
ORIC Pharmaceuticals reported strong financial results for Q1 2026, announcing the selection of rinzimetostat's recommended Phase 3 dose for the Himalayas-1 trial in post-abiraterone mCRPC. Promising early data indicates rinzimetostat's potential best-in-disease profile and a favorable safety profile compared to standard therapies. The company maintains robust cash reserves, enabling operations into 2028, with significant updates anticipated for rinzimetostat and enozertinib in the latter half of 2026.
Read more →ORICORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
ORIC Pharmaceuticals, Inc. is currently facing an investigation by the Schall Law Firm regarding potential violations of securities laws. The investigation centers on allegations that ORIC may have issued misleading information related to its prostate cancer treatment, ORIC-944. Following a disappointing program update that revealed the treatment's effectiveness is on par with a competing drug, ORIC's stock price plummeted 41%. Investors who have incurred losses are encouraged to seek legal representation.
Read more →ORIC▲ +5.1%on this newsshared move
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals presented promising preclinical data on rinzimetostat at the 2026 AACR Annual Meeting. The data highlights rinzimetostat's potential to inhibit PRC2, a key mechanism in prostate cancer treatment resistance. The findings suggest that rinzimetostat could enhance the efficacy of androgen receptor-targeted therapies across various prostate cancer models.
Read more →ORICORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims for investors of ORIC Pharmaceuticals, Inc. following a recent 26% decline in stock price. The investigation centers on whether the company and its executives complied with federal securities laws after certain clinical data disclosures. Investors who purchased ORIC securities and suffered losses are encouraged to join this investigation for potential recovery options.
Read more →ORIC▼ -41%on this newsshared move
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
ORIC Pharmaceuticals has selected rinzimetostat 400 mg once daily as the recommended Phase 3 dose in combination with darolutamide for the Himalayas-1 global trial in metastatic castration-resistant prostate cancer (mCRPC). The trial is set to begin in the first half of 2026, with early data indicating a strong safety profile and promising efficacy compared to existing therapies. The company aims to address a significant market need for effective treatments in this patient population.
Read more →ORICRinzimetostat Dose Optimization Data Update
ORIC Pharmaceuticals provided an update on the dose optimization data of Rinzimetostat, indicating its potential as a best-in-class therapy for prostate cancer. The selected dose for the first Phase 3 trial is 400 mg QD in combination with darolutamide, with favorable clinical outcomes anticipated. The drug demonstrates a differentiated safety profile with lower adverse event rates compared to competitor therapies. Both Rinzimetostat and Enozertinib are progressing toward their registrational trials within the contexts of their respective indications.
Read more →ORICORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC Pharmaceuticals will present combination dose optimization data from its Phase 1b trial of rinzimetostat for metastatic castration resistant prostate cancer (mCRPC) on March 31, 2026. The conference call will include a live Q&A session and will be accessible via the company's website. This trial aims to enhance treatment options for patients facing therapeutic resistance.
Read more →ORICORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals announced that multiple abstracts on rinzimetostat (ORIC-944) have been accepted for presentation at the 2026 AACR Annual Meeting. Rinzimetostat, a selective PRC2 inhibitor, has shown promising efficacy in treating prostate cancer, particularly in overcoming resistance mechanisms. Ongoing trials aim to further evaluate its potential in combination with androgen receptor inhibitors.
Read more →ORIC▼ -15%on this news
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
ORIC Pharmaceuticals announced inducement grants for a new employee, including 14,800 stock options and 2,400 restricted stock units. These grants are part of the company's 2022 Inducement Equity Incentive Plan and are contingent on continued employment. The grants were approved by the Compensation Committee in accordance with Nasdaq rules.
Read more →ORIC▲ +14.6%on this news
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
ORIC Pharmaceuticals reported strong fourth quarter and full year 2025 results, highlighting promising Phase 1b data for rinzimetostat and enozertinib. The company raised $264 million, providing financial stability through 2028. Anticipated milestones include multiple clinical data readouts in 2026, positioning ORIC for future registrational trials.
Read more →ORICORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
ORIC Pharmaceuticals announced the granting of stock options and restricted stock units to three new non-executive employees as part of its 2022 Inducement Equity Incentive Plan. The grants, totaling 173,800 stock options and 28,700 restricted stock units, are contingent on continued employment. This move aims to enhance talent acquisition and retention within the company.
Read more →ORICORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences in February 2026
ORIC Pharmaceuticals will participate in several investor conferences in February 2026. The company, which specializes in oncology, aims to address therapeutic resistance in cancer. Webcasts of the discussions will be available on their website, providing insights into their ongoing projects and future directions.
Read more →ORIC▲ +10.8%on this news· ran to +32% by day 3
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
ORIC Pharmaceuticals reported operational highlights for 2025, showcasing promising Phase 1b data for rinzimetostat and enozertinib. The company raised $244 million, ensuring financial stability into 2028. Upcoming milestones include multiple clinical data readouts and potential registrational trials. CEO Jacob M. Chacko emphasized the transformative progress across their pipeline.
Read more →ORICORIC Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals, Inc. announced that its CEO, Jacob M. Chacko, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will focus on the company's ongoing development of treatments targeting therapeutic resistance. A live webcast of the presentation will be accessible on the company's website, with a replay available for 90 days post-event. This marks an opportunity for ORIC to showcase its advancements and engage with potential investors.
Read more →ORICORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
ORIC Pharmaceuticals announced the granting of stock options and restricted stock units to three new non-executive employees as part of its 2022 Inducement Equity Incentive Plan. These grants, totaling 69,200 stock options and 11,400 restricted stock units, are contingent on continued employment. The approval of these grants aligns with Nasdaq regulations.
Read more →ORICORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
ORIC Pharmaceuticals presented promising data on enozertinib at the ESMO Asia Congress 2025, highlighting its strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations. The drug demonstrated a 67% overall response rate in first-line patients and a 45% response rate in second-line patients. The safety profile was competitive, with minimal off-target toxicity and manageable side effects. Further updates are anticipated in mid-2026 as the company prepares for a potential Phase 3 trial.
Read more →ORICEnozertinib (ORIC-114) Program Update
ORIC Pharmaceuticals provided an update on its enozertinib (ORIC-114) program, highlighting the drug's promising clinical profile in treating EGFR-mutated non-small cell lung cancer (NSCLC). The program shows competitive overall response rates, specifically a 67% ORR in first-line EGFR exon 20 and an 80% ORR in EGFR PACC. Additionally, enozertinib has demonstrated substantial CNS activity, making it a strong candidate for further development. The potential market opportunity is significant, estimated to be between $3.0 to $3.5 billion annually in the U.S. alone.
Read more →ORICORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
ORIC Pharmaceuticals has presented promising data for enozertinib, a treatment for NSCLC patients with EGFR exon 20 mutations, at the ESMO Asia Congress 2025. The Phase 1b trial revealed a preliminary overall response rate (ORR) of 67% in first-line (1L) patients and a 100% intracranial ORR, indicating robust systemic and central nervous system activity. The drug exhibited a favorable safety profile, with few treatment-related adverse events. Enrollment continues with updates expected in mid-2026 as the company prepares for a potential Phase 3 trial.
Read more →ORICORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
ORIC Pharmaceuticals presented data on enozertinib at the ESMO Asia Congress 2025, highlighting its efficacy in NSCLC patients with HER2 exon 20 mutations. The Phase 1b trial reported a 35% overall response rate and a manageable safety profile with low discontinuation rates. Despite these findings, the company has completed enrollment in this patient population and does not plan further development for enozertinib in this setting. A conference call is scheduled for December 6, 2025, to discuss these results further.
Read more →ORICORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
ORIC Pharmaceuticals will showcase late-breaking presentations on enozertinib (ORIC-114) at the ESMO Asia Congress 2025. The presentations will cover data from a Phase 1b trial focusing on two groups: previously treated patients with EGFR atypical mutant NSCLC and both treated and treatment-naïve patients with EGFR exon 20 mutant NSCLC. This highlights the company's ongoing research into treatments that address therapeutic resistance in cancer.
Read more →ORIC▼ -6.1%on this newsshared move
ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
ORIC Pharmaceuticals announced a poster presentation for enozertinib (ORIC-114) at the ESMO Asia Congress 2025, which will take place from December 5-7, 2025, in Singapore. The poster will feature data from a Phase 1b trial involving previously treated patients with HER2 exon 20 mutant non-small cell lung cancer (NSCLC). In conjunction with the congress, the company will also host a conference call and webcast to discuss the findings.
Read more →ORICORIC Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
ORIC Pharmaceuticals announced its participation in the 8th Annual Evercore Healthcare Conference, scheduled for December 3, 2025. The company will engage in a fireside chat and one-on-one meetings with investors at the event. The discussion will be available for streaming on the company's investor website, with replays accessible for 90 days post-event.
Read more →ORICORIC Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that
ORIC Pharmaceuticals released its financial results for the third quarter of 2025, highlighting significant advancements in its clinical trials and operational strategies. Notably, the company concluded the dose exploration phase of the ORIC-944 Phase 1b trial, showcasing its potential for best-in-class efficacy and safety. With a robust cash reserve of approximately $413 million, ORIC is positioned for continued development of its oncology programs, including upcoming clinical data readouts for both ORIC-944 and enozertinib by mid-2026. The leadership team was strengthened with the appointment of Kevin Brodbeck, PhD, as the new Chief Technical Officer.
Read more →ORICForward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation,
ORIC Pharmaceuticals has updated its forward-looking statements regarding its clinical developments, specifically for ORIC-944. The company highlights the potential best-in-class attributes of ORIC-944 but admits that these statements come with considerable risks and uncertainties. Key concerns include the variability of clinical trial outcomes and the company's ability to navigate operational challenges, such as those posed by economic and health crises. The ongoing Phase 1b clinical trials continue to assess the combination therapies involving ORIC-944.
Read more →ORICORIC Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
ORIC Pharmaceuticals has announced positive results from the Phase 1b trial of its drug ORIC-944 in combination with AR inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The data indicates a consistent and promising efficacy profile, with significant PSA response rates and notable reductions in circulating tumor DNA among treated patients. The safety analysis shows that the drug is well tolerated, with most adverse events classified as Grade 1 or 2. The company plans to present further dose optimization data in early 2026 as it prepares to initiate a Phase 3 trial later that year.
Read more →ORICORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
ORIC Pharmaceuticals announced the publication of a peer-reviewed paper detailing enozertinib, a selective EGFR inhibitor targeting exon 20 mutations in NSCLC. The study highlights its strong potency and brain-penetrance, showcasing a case where it achieved a complete response in a patient with brain metastases. ORIC anticipates sharing more clinical data in the near future.
Read more →ORICORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals will participate in several investor conferences in November 2025. The company, which specializes in oncology treatments, aims to address therapeutic resistance in cancer. Webcasts of the discussions will be accessible on their website, with replays available for 90 days post-event.
Read more →ORICORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
ORIC Pharmaceuticals presented promising preclinical data on ORIC-944 at the 2025 EORTC-NCI-AACR International Conference. The data suggest that ORIC-944, a PRC2 inhibitor, may effectively treat prostate cancer and other solid tumors. The findings indicate enhanced responses when combined with AR and KRAS inhibitors, supporting its potential as a best-in-class therapy.
Read more →ORICORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
ORIC Pharmaceuticals has appointed Dr. Kevin Brodbeck as Chief Technical Officer, a newly created role. With over 25 years of experience in technical operations and regulatory activities, Dr. Brodbeck's expertise is expected to support the company's upcoming Phase 3 trials for ORIC-944 and enozertinib. His appointment reflects ORIC's commitment to advancing its clinical programs.
Read more →ORICORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
ORIC Pharmaceuticals reported strong financial results and operational updates for Q2 2025, highlighting promising data from the Phase 1b trial of ORIC-944 in mCRPC. The company secured $244 million in financing, extending its cash runway into the second half of 2028. However, it has decided to reduce investment in discovery research and implement workforce reductions to focus on advancing its clinical pipeline.
Read more →ORICORIC Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
ORIC Pharmaceuticals has announced promising preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The trial reported a 59% PSA50 response rate and a safety profile predominantly consisting of mild to moderate adverse events. Additionally, the company secured $125 million in financing, extending its cash runway into the second half of 2027, which facilitates the continuation of its development efforts. The data supports ORIC-944's potential as a best-in-class treatment option, with further updates expected in the near future.
Read more →ORICORIC Pharmaceuticals Announces $125 Million Private Placement Financing Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare C
ORIC Pharmaceuticals announced a successful private placement financing of $125 million, led by SR One, with participation from various institutional investors. The private placement will involve selling approximately 19.2 million shares at a price of $6.50 per share, expected to close on May 29, 2025. The funds raised will support the company’s research, development, and operating plans, projected to sustain operations through 2027. ORIC's primary focus includes the ongoing Phase 3 trial for ORIC-944 in prostate cancer.
Read more →ORIC▼ -9%on this news· ran to +29% by day 3shared move
ORIC Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
ORIC Pharmaceuticals has announced that it will present initial data from its Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for patients with metastatic castration-resistant prostate cancer (mCRPC). The presentation will take place on May 28, 2025, during a conference call and webcast. ORIC-944 has demonstrated promising characteristics, including potential best-in-class properties and a favorable clinical safety profile. However, the company acknowledges potential risks affecting the continuity and success of its clinical trials and product development.
Read more →ORICORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented cor
ORIC Pharmaceuticals reported strong first-quarter 2025 financial results and progress in clinical development plans for its lead drug candidates, ORIC-944 and ORIC-114. The company announced a collaboration with Johnson & Johnson to study ORIC-114 for non-small cell lung cancer, alongside promising preclinical findings for ORIC-944 in a prostate cancer trial. With an expected total of five data readouts planned over the next 15 months, ORIC aims to initiate registrational trials for both programs in 2026. The company's cash reserves are projected to sustain operations into 2027, showcasing a solid financial position.
Read more →ORICORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals presented preclinical data on ORIC-944 at the 2025 AACR Annual Meeting, indicating its potential as a best-in-class PRC2 inhibitor for prostate cancer treatment. The data showed that ORIC-944 significantly improves progression-free survival when used with androgen receptor pathway inhibitors in various prostate cancer models. The results highlight the drug's unique ability to enhance treatment efficacy by preventing tumor adaptation and restoring critical features of cancer cells. ORIC-944 is currently being evaluated in ongoing Phase 1b trials alongside other treatments.
Read more →ORIC▼ -8.4%on this news· ran to -21% by day 1
ORIC Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals has announced that a preclinical abstract for ORIC-944, a selective allosteric inhibitor of PRC2 for treating prostate cancer, will be presented at the upcoming AACR Annual Meeting. The abstract highlights ORIC-944's ability to enhance androgen receptor signaling and restore luminal features in prostate cancer models. This drug is noted for its best-in-class properties and is currently being tested in a phase 1b trial in combination with androgen receptor pathway inhibitors. The presentation aims to showcase the potential benefits of ORIC-944 in both hormone-sensitive and resistant prostate cancer settings.
Read more →ORIC▲ +6.9%on this news
ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Anticipated registrational development plans for ORIC-944 and ORI
ORIC Pharmaceuticals has announced new registrational clinical development plans for its lead drug candidates, ORIC-944 and ORIC-114, focusing on areas with significant clinical validation and unmet medical needs. The Phase 3 trial for ORIC-944 in metastatic castration-resistant prostate cancer (mCRPC) is scheduled to start in the first half of 2026, while the initial trials for ORIC-114 are intended for first-line non-small cell lung cancer (NSCLC) in 2026. The company has also reported an extension of its cash runway until 2027, indicating improved financial stability.
Read more →ORIC▼ -6.1%on this news
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination wi
ORIC Pharmaceuticals has announced its financial results and operational updates for Q4 and the full year of 2024, highlighting significant advancements in its clinical trials, particularly for its candidates ORIC-114 and ORIC-944. The company has reported promising early safety and efficacy data for ORIC-944 in metastatic castration-resistant prostate cancer and has entered into a collaboration with Johnson & Johnson to further evaluate ORIC-114 in non-small cell lung cancer. With $256 million in cash and investments, ORIC expects to fund its operations into late 2026 and anticipates multiple data readouts over the next 18 months. The firm is gearing up for potential registrational trials for both drugs by 2025 and 2026.
Read more →ORIC▲ +8%on this news· ran to +26% by day 3
ORIC Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
ORIC Pharmaceuticals announced promising early Phase 1b data for ORIC-944's combination treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The company also revealed operational highlights, including multiple strategic collaborations and a strong cash position to support its development plans through late 2026. ORIC expects to report seven significant data readouts across its clinical programs in the next 18 months, aiming for registrational trials to begin in 2025 and 2026 for its therapies targeting NSCLC and mCRPC. Additionally, ORIC-944 demonstrated favorable safety and strong efficacy indicators in ongoing trials.
Read more →ORIC▲ +8%on this news· ran to +26% by day 3
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
ORIC Pharmaceuticals has established a clinical supply agreement with Janssen Research & Development to assess the combination of ORIC-114 and amivantamab for treating advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The trial, slated to begin in Q1 2025, will evaluate safety and tolerability, aiming to define the recommended Phase 2 dose. Initial efficacy data is anticipated to be released in mid-2026, following previous promising results from ORIC-114's monotherapy trials.
Read more →ORIC▲ +8%on this news· ran to +26% by day 3
Company Overview January 2025 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts co
ORIC Pharmaceuticals presented forward-looking statements highlighting substantial risks and uncertainties associated with their future operations and financial conditions. The company's pipeline focuses on overcoming resistance in cancer treatments, particularly through their drug candidates ORIC-114 and ORIC-944, which are set to enter pivotal studies soon. However, substantial risks remain due to the complexities of drug development, potential regulatory hurdles, and market conditions that might impact their strategic plans. Overall, while ORIC has a strong financial position, the path ahead is laden with uncertainty.
Read more →ORICORIC Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals, a clinical stage oncology company, announced that CEO Jacob M. Chacko will present an overview of the company at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. This presentation is an opportunity for ORIC to showcase its developments in combating therapeutic resistance in oncology. A live webcast of the presentation will be accessible on the company's website, with a replay available for up to 90 days post-event. The participation in such a significant conference indicates the company’s proactive outreach to investors and stakeholders.
Read more →ORICORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and
ORIC Pharmaceuticals reported positive developments during the third quarter of 2024, presenting preclinical data indicating the potential of ORIC-114 as a best-in-class treatment for EGFR exon 20 insertions. The company also announced collaborations with Bayer and Johnson & Johnson to enhance the ongoing clinical trials of ORIC-944 for prostate cancer. Despite an increase in research and development costs, ORIC maintains a solid financial position with sufficient funding to support operational growth through late 2026. Further data updates are anticipated in 2025 as the company progresses towards registrational studies for both drug candidates.
Read more →ORICORIC Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
ORIC Pharmaceuticals presented data on ORIC-114 at the EORTC-NCI-AACR Symposium, showcasing its potential as a best-in-class treatment for EGFR exon 20 insertions and atypical mutations. The drug has exhibited superior effectiveness and selectivity compared to existing therapies, with complete tumor regressions observed in preclinical models. Additional data suggest beneficial systemic and CNS responses in patients with non-small cell lung cancer. ORIC-114 continues to be evaluated in various Phase 1b cohorts, with further results anticipated in 2025.
Read more →ORICORIC Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
ORIC Pharmaceuticals announced its participation in the upcoming EORTC-NCI-AACR Symposium, where it will present its promising drug ORIC-114. This agent, focusing on EGFR and HER2 inhibitors, has shown significant effectiveness against various atypical mutations, particularly in non-small cell lung cancer patients. The presentation is scheduled for October 23, 2024, in Barcelona, Spain, where detailed findings and data on ORIC-114 will be shared to highlight its clinical potential. This showcases ORIC's ongoing commitment to advancing oncology treatment options.
Read more →ORICORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates Initiated dosing of ORIC-944 in combinations with NUBEQA (darolutamide) and ERLEADA (apalutamide) in the ongoing Phase 1b trial f
ORIC Pharmaceuticals has reported its financial results and operational updates for Q2 2024, highlighting significant progress in its clinical trials. The company has begun dosing ORIC-944 in combination with NUBEQA and ERLEADA for prostate cancer in its ongoing Phase 1b trial. Additionally, collaborations with Bayer and Johnson & Johnson have been established to support these trials. With cash reserves of $308.5 million, ORIC anticipates sufficient funding for operations into late 2026, while expanding its leadership team to strengthen its commercial and medical affairs functions.
Read more →ORIC▼ -8.7%on this news
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
ORIC Pharmaceuticals has appointed Keith Lui as the Senior Vice President of Commercial and Medical Affairs, bolstering its leadership team. Lui has over 20 years of biopharma experience and has contributed to the commercialization of multiple therapies. His appointment comes at a critical time as ORIC prepares to advance its oncology pipeline towards potential clinical development and commercialization. Lui expressed excitement about joining the team and the company's progress toward innovative cancer therapies.
Read more →ORICORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
ORIC Pharmaceuticals announced the initiation of dosing for ORIC-944 in combination with darolutamide and apalutamide as part of an ongoing Phase 1b trial for metastatic prostate cancer. The company has entered collaboration agreements with Bayer and Johnson & Johnson to support these studies, which explore the potential of ORIC-944 as a treatment strategy. The trial aims to evaluate the efficacy of ORIC-944's combination therapy, which has already shown promising results in preclinical models. This initiative may position ORIC-944 as a novel treatment option within this therapeutic area.
Read more →ORICORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR
ORIC Pharmaceuticals reported its first quarter 2024 financial results, highlighting the initiation of three Phase 1b expansion cohorts for ORIC-114 in NSCLC patients. The company also presented promising initial data for ORIC-944, indicating potential best-in-class status for prostate cancer treatment. With a strengthened cash position of $331.5 million, the company is well funded to execute its clinical development plans into late 2026. However, updated data for ORIC-114 won't be available until 2025, which poses some uncertainty.
Read more →ORICORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
ORIC Pharmaceuticals has announced the initiation of multiple Phase 1b expansion cohorts for ORIC-114, targeting patients with mutated non-small cell lung cancer (NSCLC) showcasing EGFR and HER2 alterations. Following positive data from the initial dose escalation phase, the company has selected two provisional recommended Phase 2 dose levels to optimize treatment. ORIC-114, an irreversible inhibitor, aims to address the unmet clinical needs of patients, including those with CNS metastases. The company plans to report updated trial data in the first half of 2025.
Read more →ORICORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals presented preclinical data on two promising drug candidates, ORIC-944 and ORIC-613, at the 2024 AACR Annual Meeting. ORIC-944 demonstrated superior preclinical properties and potential best-in-class efficacy as a PRC2 inhibitor, particularly in combination with AR inhibitors for prostate cancer. Meanwhile, ORIC-613 emerged as a potential first-and-best-in-class PLK4 inhibitor, showing selective lethality in TRIM37-high tumors. Both candidates display significant preclinical promise, indicating potential advancements in cancer treatment.
Read more →ORICORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with OR
ORIC Pharmaceuticals announced its fourth quarter and full year 2023 financial results, showcasing promising initial Phase 1b data from three clinical programs, particularly ORIC-944 and ORIC-114. The company emphasized the potential of these therapies as best-in-class options for cancer treatment. Financially, ORIC enjoys a robust cash position, funded through recent private placements, enough to sustain operations into late 2026. The initiation of combination studies and dose expansion cohorts for these therapies is expected in 2024, with several key milestones ahead.
Read more →ORICORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
ORIC Pharmaceuticals, Inc. has announced it will present at the Leerink Partners Global Biopharma Conference on March 13, 2024. The presentation will cover a company overview and their focus on developing therapies that combat mechanisms of therapeutic resistance in oncology. Investors can access the live webcast through the company's website, with a replay available for 90 days post-event.
Read more →ORICORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals has announced that multiple abstracts have been accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Key presentations include two oral presentations on ORIC-944, a selective PRC2 inhibitor, demonstrating promising results in prostate cancer models. Additionally, ORIC-613 has been highlighted for its potential as a first-in-class PLK4 inhibitor, offering synthetic lethality in TRIM37-high cancer models. These findings position both candidates favorably for future clinical applications.
Read more →ORICORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
ORIC Pharmaceuticals, Inc. has announced its participation in the upcoming Citi 2024 Virtual Oncology Leadership Summit, scheduled for February 21, 2024. The company's management will take part in a fireside chat during the event, which will be accessible via a live webcast on the company’s website. Additionally, a recorded version of the discussion will be available for 90 days post-event, allowing broader access for investors and interested stakeholders.
Read more →ORICORIC Pharmaceuticals Announces $125 Million Private Placement Financing Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Part
ORIC Pharmaceuticals has announced a $125 million private placement financing, involving both new and existing institutional investors, including Viking Global Investors and Commodore Capital. The financing will be conducted through the sale of approximately 12.5 million shares at a premium price of $10.00 per share. Proceeds will fund research and development of its clinical-stage product candidates and ensure the company can operate into late 2026. The transaction is expected to close on January 23, 2024, subject to customary conditions.
Read more →ORICORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
ORIC Pharmaceuticals announced promising initial Phase 1b data for ORIC-944, indicating a potential best-in-class profile for treating metastatic prostate cancer. The company highlighted robust target engagement, a favorable safety profile, and plans to initiate combination studies in 2024. Additionally, ORIC's financial stability was reinforced by an $85 million financing, estimated to fund operations through 2026, while they also anticipate multiple upcoming milestones in their clinical programs. Overall, ORIC aims to advance both ORIC-944 and ORIC-114 in addressing cancer treatments.
Read more →ORICORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals, a clinical-stage oncology company, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. CEO Jacob M. Chacko will provide a company overview, which will also be accessible via a webcast. This event showcases ORIC's ongoing efforts to engage with investors and highlight its focus on addressing therapeutic resistance in cancer treatment.
Read more →ORICCompany Overview January 2024 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts co
ORIC Pharmaceuticals, Inc. presented its forward-looking statements which involve notable risks and uncertainties concerning its future financial condition and operational results. The company highlighted its strong financial position, expecting to sustain operations into 2026 while advancing its oncology programs. However, it cautions that the timelines and outcomes of clinical trials may vary from expectations, influenced by external factors including the COVID-19 pandemic. Overall, the company maintains a focus on developing its pipeline amidst these challenges.
Read more →ORIC▼ -5.3%on this news
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Preliminary evidence of
ORIC Pharmaceuticals announced initial Phase 1 data for ORIC-533 in relapsed/refractory multiple myeloma, revealing promising clinical activity and a strong safety profile. The drug demonstrated a clean safety profile, with only mild treatment-related adverse events and no dose-limiting toxicities. Initial results indicate potential immune activation and encourage further investigation in combination therapies. The company is currently seeking strategic partnerships to support further development and extend its cash runway into 2026.
Read more →ORICORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-
ORIC Pharmaceuticals reported its third quarter 2023 financial results, highlighting initial Phase 1b data for ORIC-114, which showed promising efficacy in EGFR and HER2 exon 20 mutated non-small cell lung cancer (NSCLC). The company has reported significant CNS activity, including a complete response in a patient with untreated brain metastases. Additionally, ORIC has a robust financial cushion with $256.2 million projected to support operations through late 2025. Upcoming presentations for ORIC-533 and ORIC-944 will provide further insights into the company's developmental pipeline.
Read more →ORICORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
ORIC Pharmaceuticals announced the presentation of initial Phase 1b clinical data for its drug ORIC-533 at the upcoming ASH Annual Meeting. This drug, aimed at treating relapsed/refractory multiple myeloma, has shown a tolerable safety profile and signs of immune activation. The presentation will take place on December 11, 2023, where detailed findings regarding its efficacy and safety will be discussed. The results may provide important insights into the drug's potential to benefit patients who have limited treatment options.
Read more →ORICInitial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile CNS activity observed at multiple dose levels, including the first reported c
ORIC Pharmaceuticals has announced promising initial Phase 1 dose escalation data for ORIC-114 in treating patients with EGFR and HER2 exon 20 mutations. The data reveals significant CNS activity, including the first confirmed CNS complete response in a patient with untreated brain metastases. Systemic responses were noted in a heavily pre-treated patient population, showcasing the drug's potential efficacy following prior therapies. The company plans to advance ORIC-114 into dose optimization and registrational cohorts based on the favorable safety profile and emerging clinical data.
Read more →ORICORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
ORIC Pharmaceuticals will showcase its initial Phase 1b clinical data for ORIC-114, targeted at EGFR/HER2 exon 20 mutations in non-small cell lung cancer (NSCLC) at the ESMO Congress 2023. The congress, taking place from October 20-24 in Madrid, will feature two poster presentations detailing the study results. A conference call on October 21 will include insights from Dr. Alexander Spira, highlighting the therapeutic promise of ORIC-114. Additional preclinical data on atypical mutations will also be presented.
Read more →ORICORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
ORIC Pharmaceuticals is set to participate in the 2023 Cantor Global Healthcare Conference on September 28, 2023. The event will feature a fireside chat with management, providing insights into the company's focus on oncology treatments. A live webcast of the discussion will be available for interested investors, and replays will be accessible for 90 days post-event.
Read more →ORICORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October
ORIC Pharmaceuticals has released its financial results for Q2 2023, highlighting substantial advancements in ongoing clinical trials. The company reported strong cash reserves totaling $273.7 million, expected to sustain operations until late 2025. Initial Phase 1b clinical data for ORIC-114, targeting EGFR/HER2-mutated cancers, will be showcased at the upcoming ESMO Congress scheduled for October 20-24, 2023. The company also anticipates reporting initial data for ORIC-533 in multiple myeloma and ORIC-944 in prostate cancer in 2023 and early 2024, respectively.
Read more →ORIC▲ +27.7%on this news
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
ORIC Pharmaceuticals has announced a private placement financing agreement, raising approximately $85 million by selling around 12.1 million shares. The financing is led by Nextech and includes participation from other notable investors. The raised funds are expected to support ORIC's operations and clinical programs through late 2025, with initial clinical data from its product candidates anticipated over the next few quarters. Additionally, the agreement includes lock-up provisions for participating investors to restrict share sales.
Read more →ORICORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference
ORIC Pharmaceuticals, Inc. announced its participation in the Jefferies Healthcare Conference on June 7, 2023, where management will engage in a fireside chat. This event provides ORIC an opportunity to discuss their clinical-stage oncology developments and mechanisms of therapeutic resistance. The live discussion will be accessible via the company's investor webpage, with a replay available for 90 days post-event.
Read more →ORICORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in
ORIC Pharmaceuticals has reported financial results and operational updates for Q1 2023, highlighting ongoing clinical trials and robust financial resources. The company anticipates initial Phase 1b data for its three drug candidates, ORIC-533, ORIC-114, and ORIC-944, to be available in the latter half of 2023. They presented promising preclinical data at the 2023 AACR Annual Meeting, reinforcing the potential of their pipeline. Despite a net loss of $23.9 million for the quarter, ORIC maintains a significant cash position expected to support operations through the first half of 2025.
Read more →ORIC▼ -6.9%on this news
ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference
ORIC Pharmaceuticals, a clinical stage oncology company, announced its participation in the H.C. Wainwright BioConnect Investor Conference scheduled for May 2, 2023. The event will feature a live webcast of a fireside chat with company management, which aims to enhance investor engagement. The discussion will be accessible through their website, with a replay available for 90 days post-event. This step reflects the company’s strategy to foster communication and interest among investors.
Read more →ORIC▼ -6.5%on this news
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals presented preclinical data on their oncology pipeline at the 2023 AACR Annual Meeting. The data highlighted their ORIC-944 program, an allosteric inhibitor showing promise in treating metastatic prostate cancer, and their PLK4 inhibitor program targeting specific breast cancers. Both programs emphasize a unique biomarker strategy and selective inhibition that demonstrate therapeutic potential in resistant cancer types. The findings may pave the way for advancements in targeted cancer therapies.
Read more →ORIC▲ +15.2%on this news
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myelo
ORIC Pharmaceuticals announced its fourth quarter and full year 2022 financial results, highlighting progress in its clinical pipeline. The company is currently conducting three Phase 1b trials for its drug candidates ORIC-533, ORIC-114, and ORIC-944, with initial data expected in the latter half of 2023. In addition, ORIC received a $25 million investment from Pfizer and established a collaboration for further development of ORIC-533. The company's financial position remains strong with cash reserves that are anticipated to support operations into the first half of 2025.
Read more →ORICORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals announced that two abstracts have been accepted for poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting. The presentations will include findings on ORIC-944, an allosteric inhibitor targeting PRC2 in patients with metastatic prostate cancer, and data demonstrating the effectiveness of selective PLK4 inhibitors in breast cancer models. These presentations underscore ORIC's ongoing commitment to addressing therapeutic resistance in oncology.
Read more →ORICORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference
ORIC Pharmaceuticals, a clinical-stage oncology firm, announced that its management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 2:00 p.m. ET. This event aims to boost the company’s visibility in the healthcare sector. Investors can access the live webcast through the company's website, with replays available for 90 days following the event.
Read more →ORICORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGF
ORIC Pharmaceuticals has announced key updates regarding its clinical pipeline and financial position. The company anticipates the release of initial Phase 1b data for three ongoing clinical trials related to ORIC-533, ORIC-114, and ORIC-944 in the second half of 2023. With cash reserves of $228 million, ORIC expects to support its operations through the first half of 2025, facilitated by a recent equity investment from Pfizer. The company emphasizes progress in its drug development programs aimed at overcoming cancer resistance mechanisms.
Read more →ORICORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals, a clinical-stage oncology company, announced that CEO Jacob M. Chacko will present an overview of the company at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. This presentation will focus on ORIC's efforts in developing treatments to tackle therapeutic resistance in oncology. The event represents a significant opportunity for the company to connect with investors and communicate its strategic vision.
Read more →ORICORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer ORIC and Pfizer have entered into a clinical developme
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2 study of ORIC-533 in combi
Read more →ORIC▲ +7.8%on this news
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented preclinical ORIC-533 data demons
Read more →ORICORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will parti
Read more →ORICORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate ca
Read more →ORIC▼ -6%on this newsshared move
ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a preclinical poster prese
Read more →ORICORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate
ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H 2023
Read more →ORICORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will parti
Read more →ORIC▲ +10.6%on this news
ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Dominic Piscitelli, ch
Read more →ORIC▼ -8.2%on this news
ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate
ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H2023 Fou
Read more →ORICORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presen
Read more →ORICORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Pha
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in
Read more →ORICORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will host
Read more →ORICORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73 as a treatment for multiple myeloma ORIC-114 poster presentation to highlight compelling brain penetrant properties of an irreversible inhibitor designed to selectively
Read more →ORIC▼ -6.1%on this news
ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will parti
Read more →ORICORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced clearance of its Clinical
Read more →ORICORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones ORIC-101 program on track for updates from both ongoing clinical trials in first half of 2022 Initial Phase 1b data from ORIC-533 in m
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones ORIC-101 program on track for updates from both ongoing clinical trials in first half of 2022 Initial Phase 1b data from ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers and ORIC-9
Read more →ORICORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., c
Read more →ORIC▼ -11.3%on this news
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
CD73 inhibition overcomes immunosuppression and demonstrates activity in assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic Phase 1 trial of single agent ORIC-533, a highly potent, orally bioavaila
Read more →ORICORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma
Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting Senior author Dr. Kenneth Anderson to discuss beneficial effects of ORIC CD73 inhibitor on restoring human an
Read more →ORICORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO and
ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO and SAN DIEGO, CA November 10, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic
Read more →ORICORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide and preclinical data on ORIC-114 presented a
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide and preclinical data on ORIC-114 presented at AACR-NCI-EORTC Update on oral CD73 inhibitor program to
Read more →ORICORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
CD73 inhibition overcomes immune suppression and demonstrates activity in autologous ex vivo cell assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic Phase 1 trial of single agent ORIC-533, a highly
Read more →ORIC▼ -35.4%on this news
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC ORIC-101 and enzalutamide combination regimen at the
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally
Read more →ORICORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced three poster presentation
Read more →ORICORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced an update on its CD73 inhibitor p
Read more →ORICORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors SOUTH SAN FRANCISCO and
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors SOUTH SAN FRANCISCO and SAN DIEGO, CA August 16, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic r
Read more →ORICORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation of Phase 1
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation of Phase 1 trial expected in 2H21 IND/CTA filings for ORIC-944 and O
Read more →ORICORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor ORIC expects to initiate single agent clinical trial in an undisclosed tumo
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor to initiate single agent clinical trial in an undisclosed tumor type in 2H21 filing is the first of three IND/CTA filings expected i
Read more →ORICORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events prim
Read more →ORICORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., ch
Read more →ORICORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will host
Read more →ORICORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 ex
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO and SAN DIEGO, CA - Ma
Read more →ORICORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that two abstracts highli
Read more →ORICORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at
Read more →ORICORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Lead program ORIC-101 on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Lead program ORIC-101 on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 Cash, Cash Equivalents and Investme
Read more →ORICORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster pre
Read more →ORICORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data re
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944,
Read more →ORICORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., c
Read more →ORICORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101
Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study Expansion cohorts will enroll patients with pancreatic ductal adenocarcinoma, ovarian cancer, triple negat
Read more →ORICORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its previou
Read more →ORICORIC Pharmaceuticals Announces Pricing of Upsized Public Offering
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of an upsized
Read more →ORICORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has commenced an u
Read more →ORICORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update Expanded precision oncology pipeline through in-licensing of allosteric PRC2 inhibitor program and brain penetrant EGFR and HER2 exon 20 in
ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update Expanded precision oncology pipeline through in-licensing of allosteric PRC2 inhibitor program and brain penetrant EGFR and HER2 exon 20 inhibitor program Lead program ORIC-101 on track for multip
Read more →ORICORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and sel
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2
Read more →ORICORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020
SOUTH SAN FRANCISCO and SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation and oral dis
Read more →ORICORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update Lead program ORIC-101 on track for multiple interim data readouts in 2021 and CD73 inhibitor ORIC-533 on track for IND filing in first hal
ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update Lead program ORIC-101 on track for multiple interim data readouts in 2021 and CD73 inhibitor ORIC-533 on track for IND filing in first half of 2021 Licensed exclusive worldwide development and co
Read more →ORICORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics
ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor IND filing to support clinical development of ORIC-944 in prostate cancer expected in 2H 2021 ORIC to host conference call today at 4:30 p.m. ET SOUTH SAN FRA
Read more →ORICORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will host
Read more →ORICORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today presented preclinical data from the company’s gluc
Read more →ORICORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors SOUTH SAN FRANCISCO, CA - June 9, 2020 - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, to
Read more →ORICORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple poster presentations highli
Read more →ORICORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive
Read more →ORICORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results Successful completion of $138.0 million initial public offering; cash and cash equivalents of $204.2 million as of April 30 th expected to
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results Successful completion of $138.0 million initial public offering; cash and cash equivalents of $204.2 million as of April 30th expected to fund current operating plan into 2023 Lead program ORIC-10
Read more →ORICORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares South San Francisco, CA
ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares South San Francisco, CA - April 28, 2020 - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing
Read more →ORICORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting
Orally bioavailable small molecule CD73 inhibitors reverse immunosuppression by blocking adenosine production Internal research program led to discovery of clinical candidate ORIC-533, which in preclinical studies demonstrated significant anti-tumor single agent efficacy SOUTH
Read more →ORICORIC Pharmaceuticals Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of its initial public offer
Read more →ORICORIC Pharmaceuticals Appoints Ashraf Hanna, PhD, MD, as Chief Executive Officer, and Darcy Mootz, PhD, as Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, a privately-held oncology company focused on the discovery and development of drugs targeting treatment-resistant cancers, announced today the appointments of Ashraf Hanna, PhD, MD, as Chief Exec
Read more →Competitive Position
How ORIC ranks across every disease it competes inCompetitive Position is a premium feature
See how ORIC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial